Low testosterone is a downstream effect. That phrase from the @efhcoaching post landed 78 likes on a simple image because it crystallizes something most men’s health doctors will never say out loud: the testosterone number on your labs is not the problem — it is the readout of a problem that exists somewhere upstream.
Putting a man on TRT without finding the upstream cause is like changing the oil warning light bulb instead of checking the engine. Here are the five most common upstream drivers and the sequence to address them before you ever touch exogenous testosterone.
Why Low Testosterone Is Almost Always Secondary
Primary hypogonadism — actual testicular failure where the Leydig cells cannot produce testosterone regardless of LH stimulation — is relatively rare. It happens with Klinefelter syndrome, testicular injury, chemotherapy, radiation, and severe infections. It is not what most men walking into a TRT clinic have.
What most men have is secondary or functional hypogonadism: the testes are capable of producing testosterone, but the upstream signals telling them to do so are impaired. LH and FSH from the pituitary are low or inadequate. The hypothalamus is undersecreating GnRH. Or peripheral factors like aromatase and SHBG are distorting the picture entirely.
Fix the upstream signal and testosterone normalizes. Skip that step and you are on TRT for life while the actual problem continues to cause damage.
Driver 1: Gut Dysbiosis and the Estrogen-Aromatase Loop
The gut microbiome maintains a collection of bacteria collectively called the estrobolome — species that express beta-glucuronidase, an enzyme that deconjugates estrogens that the liver has already processed for excretion. When these bacteria are overgrown, they recirculate estrogens that should be leaving the body.
Elevated recirculating estrogen increases aromatase expression in adipose tissue. Aromatase converts testosterone to estradiol. More aromatase means more T-to-E2 conversion, which means lower testosterone and higher estradiol, which feeds back on the hypothalamus to suppress GnRH, which suppresses LH, which reduces testicular testosterone production further.
It is a loop. Gut dysbiosis drives it. No amount of TRT breaks the loop — it just adds more testosterone to a system that will convert it to estrogen.
The intervention: fix the gut first. BPC-157 is particularly useful here because it repairs gut barrier function (reducing the LPS-driven systemic inflammation that worsens the dysbiosis), improves gut motility, and has direct anti-inflammatory effects that lower the inflammatory drive on aromatase.
BPC-157 (Body Protection Compound) — SwissChems: 250mcg subcutaneously daily. Run this for 8-12 weeks while addressing diet and microbiome before reassessing testosterone levels.
Driver 2: Liver Dysfunction and SHBG Dysregulation
The liver produces sex hormone binding globulin (SHBG), which binds testosterone in circulation and renders it biologically inactive. Only the fraction of testosterone not bound to SHBG or albumin (called free testosterone) can enter cells and act.
Liver inflammation, fatty liver, and impaired liver detoxification all alter SHBG production and slow the clearance of estrogen metabolites. A man can have total testosterone of 600 ng/dL but free testosterone in the basement if SHBG is elevated — which is common in men with subclinical liver dysfunction, insulin resistance, and thyroid issues.
The fix: liver support through diet (removing alcohol, refined seed oils, processed sugar), liver-supportive compounds (TUDCA, NAC, milk thistle), addressing the gut dysbiosis driving LPS-mediated liver inflammation, and — if warranted — checking for fatty liver via ultrasound or liver enzyme elevation on labs.
Driver 3: Chronic Cortisol Elevation
Cortisol and testosterone share a precursor: pregnenolone. Under chronic stress, the adrenal glands redirect pregnenolone toward cortisol production — a phenomenon sometimes called pregnenolone steal, though the mechanism is more nuanced than simple substrate competition. More relevant is that chronic HPA axis activation directly suppresses the HPG (hypothalamic-pituitary-gonadal) axis at the level of the hypothalamus, reducing GnRH pulsatility.
Additionally, cortisol at high concentrations competes with testosterone at the androgen receptor, reducing the effective tissue response to whatever testosterone is present.
In practical terms: a man working 70-hour weeks, sleeping poorly, and under chronic financial or relationship stress will often have low-normal testosterone that normalizes when the stressors resolve. Putting him on TRT before addressing stress physiology is treating a symptom of a lifestyle problem.
Driver 4: Sleep Deprivation
This one is quantified and should be cited more often. A 2011 study in JAMA found that one week of sleep restriction to five hours per night reduced testosterone levels by 10-15% in young healthy men. LH pulses — the pituitary signal that drives testicular testosterone production — occur predominantly during deep sleep stages 3 and 4. If you are not reaching adequate slow-wave sleep, the signal is not being sent.
Sleep apnea compounds this significantly. Men with untreated obstructive sleep apnea have dramatically lower testosterone than matched controls, and treating the apnea often normalizes testosterone without any other intervention. If a man has low testosterone and snores, getting a sleep study is a non-negotiable first step.
Driver 5: Systemic Inflammation and Leydig Cell Suppression
Even when the HPG axis signal is intact, the Leydig cells in the testes can be directly suppressed by inflammatory cytokines. IL-6, TNF-alpha, and IL-1beta all directly impair steroidogenesis in Leydig cells by downregulating the key rate-limiting step: StAR protein (steroidogenic acute regulatory protein), which transports cholesterol into the mitochondria where testosterone synthesis begins.
Chronic low-grade inflammation from gut dysbiosis, metabolic syndrome, poor sleep, and overtraining suppresses StAR expression and blunts Leydig cell output. This is why anti-inflammatory interventions — fixing the gut, improving sleep, managing training load, losing visceral fat — often raise testosterone in men with low-normal levels without any hormonal intervention.
The Right Sequence Before TRT
- Labs first — Total T, Free T, E2 (sensitive assay), LH, FSH, SHBG, thyroid panel (Free T3/T4, TSH), CMP, CBC, sIgA stool test, sleep study if indicated
- Fix gut dysbiosis — SIBO testing and treatment if indicated, BPC-157 for gut repair, address diet
- Address sleep — 8 hours minimum, treat apnea if present, no alcohol within 3 hours of sleep
- Manage inflammation and cortisol — training load, stress management, remove processed foods and seed oils
- Retest at 90 days — in most men with functional hypogonadism, these interventions alone raise testosterone meaningfully
- If still low, consider Enclomiphene — Enclomiphene is a selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the hypothalamus and pituitary, increasing GnRH, LH, and FSH pulsatility, which stimulates endogenous testosterone production. It raises testosterone while maintaining testicular size and fertility — unlike TRT, which suppresses LH/FSH and causes testicular atrophy
Enclomiphene Citrate — SwissChems: 12.5-25mg daily. Clean SERM that stimulates endogenous production without the side effects of the racemic clomiphene (which includes the estrogenic zuclomiphene isomer that causes vision issues and mood problems in some men). The right tool between lifestyle optimization and TRT.
When TRT Is Actually the Right Call
Primary hypogonadism confirmed by low LH/FSH alongside low testosterone (meaning the testes are failing despite adequate signaling) is a legitimate indication for TRT. So is age-related decline in a man who has genuinely exhausted upstream interventions and still has symptomatic hypogonadism at 55 or 60.
But most men getting TRT prescriptions today are in their 30s with functional hypogonadism driven by poor sleep, gut dysfunction, metabolic syndrome, and chronic stress. For them, TRT is shutting down their remaining endogenous production, creating dependency, and leaving the actual problem completely untouched.
Tossing someone on TRT without fixing the issue is exactly as dumb as it sounds.